Literature DB >> 23114524

Recombinant factor VIIa as haemostatic therapy in advanced liver disease.

Pier Mannuccio Mannucci1, Massimo Franchini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23114524      PMCID： PMC3827390          DOI： 10.2450/2012.0066-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  37 in total

1.  The risk associated with aprotinin in cardiac surgery.

Authors:  Dennis T Mangano; Iulia C Tudor; Cynthia Dietzel
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

2.  Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events?

Authors:  Dominique Thabut; Marika Rudler; Géraldine Rousseau; Thierry Poynard
Journal:  J Hepatol       Date:  2011-02-22       Impact factor: 25.083

Review 3.  The coagulopathy of chronic liver disease.

Authors:  Armando Tripodi; Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

4.  Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.

Authors:  Jerrold H Levy; Abe Fingerhut; Thomas Brott; Irene H Langbakke; Elisabeth Erhardtsen; Robert J Porte
Journal:  Transfusion       Date:  2006-06       Impact factor: 3.157

5.  Recombinant activated factor VII for adjunctive hemorrhage control in trauma.

Authors:  U Martinowitz; G Kenet; E Segal; J Luboshitz; A Lubetsky; J Ingerslev; M Lynn
Journal:  J Trauma       Date:  2001-09

6.  Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation.

Authors:  Piotr Kaliciński; Małgorzata Markiewicz; Andrzej Kamiński; Przemysław Laniewski; Hor Ismail; Tomasz Drewniak; Marek Szymczak; Paweł Nachulewicz; Elzbieta Jezierska
Journal:  Pediatr Transplant       Date:  2005-06

7.  Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.

Authors:  J Peter A Lodge; Sven Jonas; Robert M Jones; Michael Olausson; José Mir-Pallardo; Soeren Soefelt; Juan Carlos Garcia-Valdecasas; Vivian McAlister; Darius F Mirza
Journal:  Liver Transpl       Date:  2005-08       Impact factor: 5.799

Review 8.  Coagulation defects in liver disease.

Authors:  E F Mammen
Journal:  Med Clin North Am       Date:  1994-05       Impact factor: 5.456

9.  Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy.

Authors:  Lennox Jeffers; Naga Chalasani; Luis Balart; Nikolaos Pyrsopoulos; Elisabeth Erhardtsen
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

Review 10.  Prophylactic activated recombinant factor VII in liver resection and liver transplantation: systematic review and meta-analysis.

Authors:  Norberto C Chavez-Tapia; Roberto Alfaro-Lara; Felix Tellez-Avila; Tonatiuh Barrientos-Gutiérrez; Octavio González-Chon; Nahum Mendez-Sanchez; Misael Uribe
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240
View more
  2 in total

Review 1.  Transfusion strategies in patients with cirrhosis.

Authors:  Patricia Liu; Justine Hum; Janice Jou; Richard M Scanlan; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2019-11-19       Impact factor: 2.997

2.  Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope.

Authors:  Xingshun Qi; Chun Ye; Xiaozhong Guo
Journal:  Arch Med Sci       Date:  2017-01-23       Impact factor: 3.318
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.